|会社名||Collegium Pharmaceuticals Inc （コレギウム・ファ―マシュ―ティカル）|
|分野（sector）||Health Care ヘルスケア|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 コレギウム・ファーマシューティカル（Collegium Pharmaceutical Inc.）は特殊医薬品会社である。同社は、慢性疼痛及びその他疾患の治療用「DETERx」プラットフォーム技術を組み込んだ乱用防止製品の開発・製品化を行う。同社の製品はXtampza ERとONSOLISを含む。DETERxプラットフォームは、鎮痛、咀嚼、加熱および注射を含む一般的な乱用と改ざんの方法に対して保護しながら、徐放性ドラッグデリバリーを提供する。Xtampza ERは、一般的な乱用と偶発的な誤用を受けた後、徐放性薬物放出プロファイルを維持しながら、適切な疼痛管理を提供するように設計された。ONSOLISは、永続的な癌の痛みのために既にオピオイド療法を受けて耐性がある18歳以上のがん患者（BTPc）における突破痛の管理を目的とする経粘膜即時放出フェンタニル（TIRF）フィルムである。 コレギウム・ファ―マシュ―ティカルは米国の製薬会社。慢性疼痛および他の疾患の治療用に開発された特許取得済みプラットフォ―ム技術「DETERx」を組み込んだ、次世代の医薬品の開発、製品化を手掛ける。開発中の医薬品に「Xtampza ER」や「Xtampza」がある。 Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.|
|本社所在地||780 Dedham Street Suite 800 Canton MA 02021 USA|
|代表者氏名||Michael Thomas Heffernan マイケル・トーマス・ヘファナン|
|代表者役職名||Chairman of the Board President 取締役会長会長|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Collegium Pharmaceutical Inc revenues increased from $5.7M to $136.8M. Net loss decreased 28% to $31.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Income increase from $235K to $646K (income) Research and Development decrease of 1% to $3.8M (expense).|
Collegium Pharmaceutical, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:COLL) 2022/05/16 17:37:57 Seeking Alpha
The following slide deck was published by Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call Transcript 2022/05/11 02:45:07 Seeking Alpha
Collegium Pharmaceutical, Inc. (NASDAQ:NASDAQ:COLL) Q1 2022 Earnings Conference Call May 10, 2022 04:30 PM ET Company Participants Alex Dasalla - Head of IR & Corporate Communications…
Collegium Pharmaceutical GAAP EPS of -$0.39, revenue of $83.75M 2022/05/10 20:29:08 Seeking Alpha
Collegium Pharmaceutical press release (COLL): Q1 GAAP EPS of -$0.39.Revenue of $83.75M (-4.5% Y/Y).2022 Guidance: Total product revenues are expected in the range of $450.0 million…
Collegium Pharmaceutical Q1 2022 Earnings Preview 2022/05/09 21:35:48 Seeking Alpha
Collegium Pharmaceutical (COLL) is scheduled to announce Q1 earnings results on Tuesday, May 10, after market close.The consensus EPS estimate is $0.90 and the consensus revenue estimate…
Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results 2022/04/26 20:00:00 GlobeNewswire
STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2022 at 4:30 p.m. ET. The Company will discuss its first quarter 2022 financial results and provide a corporate update.
Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference 2021/09/13 12:00:00 Intrado Digital Media
STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations highlighting data regarding its product portfolio were presented at the Annual PAINWeek National Conference, which took place September 7-11, 2021 in Las Vegas, NV.
Collegium to Participate in Upcoming Investor Conferences 2021/09/01 20:01:00 Intrado Digital Media
STOUGHTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences during the month of September:
Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2021 Results - Earnings Call Transcript 2021/08/07 19:27:06 Seeking Alpha
Collegium Stock Is Getting Beaten As Q2 Earnings Miss Street Estimates; Revises FY21 Guidance 2021/08/06 16:21:40 Business Insider Markets
Collegium Pharmaceutical Inc (NASDAQ: COLL ) reported Q2 adjusted EPS of $0.27, below the consensus of $0.36.
Collegium Pharmaceutical, Inc. 2021 Q2 - Results - Earnings Call Presentation 2021/08/06 14:37:19 Seeking Alpha
Collegium Pharmaceutical Inc (COLL) falls -1.8060% for June 17 - Equities News 2021/06/22 11:12:27 Equities
Collegium Pharmaceutical Inc (COLL) falls -1.8060% for June 17 Equities.com
Collegium Announces Publication of Real-World Data in Journal of Pain Research 2021/06/16 20:01:00 Benzinga
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL ), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, "Nonmedical Use of Xtampza ® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-world Data from the Addiction Severity Index Multimedia Version (ASI-MV ® )," was published in the peer-reviewed medical journal, Journal of Pain Research . "An important part of our commitment to responsible pain management includes ongoing surveillance of real-world data assessing the incidence of abuse, misuse and diversion related to our product portfolio," said Richard Malamut, M.D., Executive Vice President and Chief Medical Officer of Collegium. "We will continue to support the analysis and publication of real-world data as it becomes available. We believe it is important for the medical and scientific communities to have access to these data to inform treatment decisions when prescribing effective analgesic therapy to treat people suffering from pain." While the analysis reported in this publication contributes to an understanding of the relative rates of nonmedical use of various opioid products, nothing in the findings should be construed as suggesting that Xtampza ER (oxycodone) extended-release capsules, does not have a high potential for addiction, abuse, or misuse.
Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL) 2021/05/28 13:15:12 Smarter Analyst
Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $34.00. The post Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .
Collegium to Participate in Upcoming Investor Conference - May 20, 2021 2021/05/20 00:00:00 BioSpace
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conference
Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL) 2021/05/14 13:55:31 Smarter Analyst
In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL), with a price target of $34.00. The post Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .
関連キーワード （医薬品 米国株 コレギウム・ファ―マシュ―ティカル COLL Collegium Pharmaceutical Inc.）